Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Chimeric Therapeutics Ltd. ( (AU:CHM) ) is now available.
Chimeric Therapeutics has issued a transaction-specific prospectus under the Australian Corporations Act to support a structured capital raising. The offer is targeted primarily at existing placement subscribers and a specific noteholder, and the securities are described as speculative and subject to distribution restrictions outside Australia.
The capital structure includes attaching options for each placement share, convertible notes with an aggregate face value of $4 million, and warrants valued at $2 million, plus up to 50 million adviser options for the joint lead managers. This complex mix of equity-linked instruments underscores the company’s reliance on higher-risk funding and may significantly affect its capital base and dilution profile for existing shareholders.
The most recent analyst rating on (AU:CHM) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Chimeric Therapeutics Ltd. stock, see the AU:CHM Stock Forecast page.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics Ltd. is an Australian biotechnology company focused on developing cell-based immunotherapies, with its shares listed on the ASX. The company operates in a high-risk, speculative segment of the life sciences and capital markets, relying on equity and structured securities offerings to fund its research, development, and corporate activities.
Technical Sentiment Signal: Sell
Current Market Cap: A$8.84M
See more data about CHM stock on TipRanks’ Stock Analysis page.